Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class I · High risk

1% LIDOCAINE HCl Injection

Presence of Particulate Matter: Confirmed customer complaint that orange and black particulates, identified as iron oxide, were found embedded within the glass vial and floating in solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-4279-02 D-0382-2015
Class III · Low risk

Triveen - PRx RNF Capsules

Labeling: Not Elsewhere Classified: Label indicates that the product contains Vitamin B12 (12 micrograms) on the Supplement Facts panel, however, the formulation of this product does not contain Vitamin B12.

Terminated Labeling / mix-up Trigen Laboratories, Inc. NDC 13811-558-30 D-1544-2014
Class III · Low risk

Wockhardt Metoprolol Succinate

Failed Dissolution Specifications: Product was out of specification (OOS) at the 12 month long term stability testing point.

Terminated Dissolution failure Wockhardt Usa Inc. NDC 64679-735-02 D-0304-2015
Class II · Moderate risk

Pristiq (desvenlafaxine)

Presence of Foreign Tablets/Capsules: Pfizer is recalling 50 mg Pristiq (desvenlafaxine) extended release tablets because a single Pristiq 100 mg tablet was found in a bottle of 50 mg Pristiq.

Terminated Particulate / foreign matter Pfizer Us Pharmaceutical Group NDC 0008-1211-30 D-1409-2014
Class I · High risk

Super ARTHGOLD 500mg

Marketed Without an Approved NDA/ANDA; Product contains undeclared indomethacin, diclofenac, and chlorzoxazone.

Terminated Chemical / undeclared Sung Soo Kim D-1535-2014
Class II · Moderate risk

phosLo (calcium acetate)

Cross Contamination with Other Products: Potential for contaminant on the cotton packaging inside the bottle. Chemical analysis of the contaminant found on the cotton was identified as a formulation of 4% Trimipramine methanesulfonate - a tricyclic antidepressant..

Terminated Cross-contamination Fresenius Medical Care Holdings, Inc. NDC 0781-2081-02 D-1343-2014
Class III · Low risk

Oxandrolone Tablets

Labeling: Missing Label; Three cases of product (total of 36 bottles) were packaged without the primary label on the bottle. The cases were, however, packaged in the correct finished product shipper, labeled with the correct shipper bar code label, sealed with tamper-evident tape and erroneously shipped to Upsher-Smith.

Terminated Labeling / mix-up Upsher Smith Laboratories, Inc. NDC 0245-0272-06 D-1255-2014
Class III · Low risk

Haloperidol Decanoate Injection

Failed Impurities/Degradation Specifications: Fresenius Kabi is recalling three lots of Haloperidol Decanoate Injection due to an out-of-specification result.

Terminated Impurity / degradation Fresenius Kabi USA LLC NDC 63323-469-01 D-0247-2015
Class II · Moderate risk

Muro 128 (sodium chloride)

Crystallization: Crystal precipitate formation and an increase in the number of complaints associated with a gritty, sand-like feeling in the eye.

Terminated Failed specification Bausch & Lomb, Inc. NDC 24208-385-01 D-1410-2014
Class I · High risk

Thinogenics

Marketed Without an Approved NDA/ANDA: Product contains undeclared sibutramine.

Terminated Chemical / undeclared Nature's Universe D-1594-2014
Class II · Moderate risk

Gemcitabine For Injection USP

Lack of Assurance of Sterility: A particle excursion for a different batch of the same product may lead to a lack of sterility assurance.

Terminated Sterility / contamination Caraco Pharmaceutical Laboratories, Ltd. NDC 47335-154-40 D-1407-2014
Class II · Moderate risk

Pantoprazole Sodium

Correct Labeled Product Miscart/Mispack: some cartons labeled as Pantoprazole Sodium Delayed-Release may contain correctly labeled blister cards of Lorazepam tablets

Terminated Labeling / mix-up Legacy Pharmaceutical Packaging NDC 0904-6235-61 D-1363-2014
Class II · Moderate risk

Tikosyn¿ (dofetilide)

Presence of Foriegn Tablets/Capsules: A single Tikosyn¿ (dofetilide) 250 mcg capsule was discovered in one bottle of Tikosyn¿ (dofetilide) 500 mcg (0.5 mg).

Terminated Particulate / foreign matter Pfizer Inc. NDC 00069-5820-60 D-1253-2014

Recalls by year